Congenital factor XI deficiency: An update

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 6, 2013, Pages 621-631

  Duga, Stefano ^a   Salomon, Ophira ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

animal models; antithrombosis; bleeding; factor XI; genetics; global coagulation test; inhibitors; molecular diagnosis; thrombosis

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 ANTIPLASMIN; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTITHROMBIN; APROTININ; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD CLOTTING FACTOR XI CONCENTRATE; COMPLEMENT COMPONENT C1S INHIBITOR; FRESH FROZEN PLASMA; GLUTAMIC ACID; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HOMEOPATHIC AGENT; IMMUNOGLOBULIN; LEUCINE; MESSENGER RNA; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDOMIMETIC AGENT; PHENYLALANINE; PROTEASE NEXIN; PROTEASE NEXIN 2; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SERINE PROTEINASE INHIBITOR; THROMBIN; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMINO ACID SUBSTITUTION; APPENDECTOMY; ARTERY THROMBOSIS; ARTICLE; BLEEDING DISORDER; BLOOD; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING TEST; CLINICAL EVALUATION; CRYSTAL STRUCTURE; DISEASE SEVERITY; DRUG EFFICACY; ELASTOGRAPHY; EXON; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INHERITANCE; LABORATORY TEST; LIVER CELL; LOW DRUG DOSE; MISSENSE MUTATION; MOLECULAR DIAGNOSIS; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; POINT MUTATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SURGICAL TECHNIQUE; SYMPTOM; THROMBOCYTE ACTIVATION; THROMBOCYTE DISORDER; THROMBOELASTOGRAPHY; THROMBOELASTOMETRY; VEIN THROMBOSIS;

ANIMALS; FACTOR XI; FACTOR XI DEFICIENCY; FOUNDER EFFECT; HEMORRHAGE; HUMANS; MICE; MICE, KNOCKOUT; MUTATION; THROMBOSIS;

EID: 84883219465     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1353420     Document Type: Article

References (108)

1. Emsley J., McEwan P. A., Gailani D. Structure and function of factor XI. Blood: 2010; 115 13 2569 2577
2. Rosenthal R. L., Dreskin O. H., Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med: 1953; 82 1 171 174
3. Salomon O., Steinberg D. M., Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia: 2006; 12 5 490 493
4. Bolton-Maggs P. H. Factor XI deficiency-resolving the enigma? Hematology (Am Soc Hematol Educ Program): 2009; 97 105
5. Kravtsov D. V., Wu W., Meijers J. C., et al. Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood: 2004; 104 1 128 134
6. Kravtsov D. V., Monahan P. E., Gailani D. A classification system for cross-reactive material-negative factor XI deficiency. Blood: 2005; 105 12 4671 4673
7. Dai L., Rangarajan S., Mitchell M. Three dominant-negative mutations in factor XI-deficient patients. Haemophilia: 2011; 17 5 e919 e922
8. Mitchell M., Mountford R., Butler R., et al. Spectrum of factor XI (F11) mutations in the UK population-116 index cases and 140 mutations. Hum Mutat: 2006; 27 8 829
9. Shpilberg O., Peretz H., Zivelin A., et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood: 1995; 85 2 429 432
10. Zadra G., Asselta R., Tenchini M. L., et al. Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians. Haematologica: 2008; 93 5 715 721
11. Salomon O., Seligsohn U. New observations on factor XI deficiency. Haemophilia: 2004; 10 04 184 187
12. Bouma B. N., Meijers J. C. Role of blood coagulation factor XI in downregulation of fibrinolysis. Curr Opin Hematol: 2000; 7 5 266 272
13. Bolton-Maggs P. H., Patterson D. A., Wensley R. T., Tuddenham E. G. Definition of the bleeding tendency in factor XI-deficient kindreds-a clinical and laboratory study. Thromb Haemost: 1995; 73 2 194 202
14. Kadir R. A., Economides D. L., Sabin C. A., Owens D., Lee C. A. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet: 1998; 351 9101 485 489
15. Salomon O., Zivelin A., Livnat T., et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood: 2003; 101 12 4783 4788
16. Salomon O., Zivelin A., Livnat T., Seligsohn U. Inhibitors to Factor XI in patients with severe Factor XI deficiency. Semin Hematol: 2006; 43 1 01 S10 S12
17. Zucker M., Zivelin A., Teitel J., Seligsohn U. Induction of an inhibitor antibody to factor XI in a patient with severe inherited factor XI deficiency by Rh immune globulin. Blood: 2008; 111 3 1306 1308
18. Quélin F., Trossaërt M., Sigaud M., Mazancourt P. D., Fressinaud E. Molecular basis of severe factor XI deficiency in seven families from the west of France. Seven novel mutations, including an ancient Q88X mutation. J Thromb Haemost: 2004; 2 1 71 76
19. Salomon O., Steinberg D. M., Koren-Morag N., Tanne D., Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood: 2008; 111 8 4113 4117
20. Yang D. T., Flanders M. M., Kim H., Rodgers G. M. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol: 2006; 126 3 411 415
21. Davis J., Wagner M. R., Zhang W., Xu F., Van Nostrand W. E. Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. J Biol Chem: 2003; 278 21 19054 19061
22. Bolton-Maggs P. H., Peretz H., Butler R., et al. A common ancestral mutation (C128X) occurring in 11 non-Jewish families from the UK with factor XI deficiency. J Thromb Haemost: 2004; 2 6 918 924
23. Umeda T., Hiramaru M., Nishino T., Onchi K., Matsuda T. A case of congenital factor XI (plasma thromboplastin antecedent) deficiency with large organized thrombus in the vena cava inferior. [in Japanese]. Nippon Ketsueki Gakkai Zasshi: 1968; 31 3 325 333
24. Brodsky J. B., Burgess G. E. III. Pulmonary embolism with factor XI deficiency. JAMA: 1975; 234 11 1156 1157
25. Evans G., Pasi K. J., Mehta A., Lee C. A., Perry D. J. Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency. Blood Coagul Fibrinolysis: 1997; 8 7 437 440
26. Salomon O., Steinberg D. M., Zucker M., Varon D., Zivelin A., Seligsohn U. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost: 2011; 105 2 269 273
27. Meijers J. C., Tekelenburg W. L., Bouma B. N., Bertina R. M., Rosendaal F. R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med: 2000; 342 10 696 701
28. Etscheid M., Breitner-Ruddock S., Gross S., Hunfeld A., Seitz R., Dodt J. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang: 2012; 102 1 40 46
29. Tucker E. I., Gailani D., Hurst S., Cheng Q., Hanson S. R., Gruber A. Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. J Infect Dis: 2008; 198 2 271 274
30. Tucker E. I., Verbout N. G., Leung P. Y., et al. Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood: 2012; 119 20 4762 4768
31. Luo D., Szaba F. M., Kummer L. W., et al. Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis. Infect Immun: 2012; 80 1 91 99
32. Itakura A., Verbout N. G., Phillips K. G., et al. Activated factor XI inhibits chemotaxis of polymorphonuclear leukocytes. J Leukoc Biol: 2011; 90 5 923 927
33. Salomon O., Steinberg D. M., Tamarin I., Zivelin A., Seligsohn U. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis: 2005; 16 1 37 41
34. Myers B., Pavord S., Kean L., Hill M., Dolan G. Pregnancy outcome in Factor XI deficiency: incidence of miscarriage, antenatal and postnatal haemorrhage in 33 women with Factor XI deficiency. BJOG: 2007; 114 5 643 646
35. Tarantino M. D., Gupta S. L., Brusky R. M. The incidence and outcome of intracranial haemorrhage in newborns with haemophilia: analysis of the Nationwide Inpatient Sample database. Haemophilia: 2007; 13 4 380 382
36. Singh A., Harnett M. J., Connors J. M., Camann W. R. Factor XI deficiency and obstetrical anesthesia. Anesth Analg: 2009; 108 6 1882 1885
37. Setty S., Reddell A., England A., Gomez K., Kadir R. The role of recombinant factor VIIa for obstetric block in women with severe factor XI deficiency. Haemophilia: 2011; 17 6 906 909
38. Peretz H., Mulai A., Usher S., et al. The two common mutations causing factor XI deficiency in Jews stem from distinct founders: one of ancient Middle Eastern origin and another of more recent European origin. Blood: 1997; 90 7 2654 2659
39. Zivelin A., Bauduer F., Ducout L., et al. Factor XI deficiency in French Basques is caused predominantly by an ancestral Cys38Arg mutation in the factor XI gene. Blood: 2002; 99 7 2448 2454
40. Bolton-Maggs P. HB, Young Wan-Yin B., McCraw A. H., Slack J., Kernoff P. B. Inheritance and bleeding in factor XI deficiency. Br J Haematol: 1988; 69 4 521 528
41. Wu W., Li H., Navaneetham D., Reichenbach Z. W., Tuma R. F., Walsh P. N. The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis. Blood: 2012; 120 3 671 677
42. Younis H. S., Crosby J., Huh J. I., et al. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood: 2012; 119 10 2401 2408
43. Minnema M. C., Friederich P. W., Levi M., et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest: 1998; 101 1 10 14
44. Kleinschnitz C., Stoll G., Bendszus M., et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med: 2006; 203 3 513 518
45. Rosen E. D., Gailani D., Castellino F. J. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost: 2002; 87 4 774 776
46. Yamashita A., Nishihira K., Kitazawa T., et al. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J Thromb Haemost: 2006; 4 7 1496 1501
47. Rugonyi S., McCarty O. J., Gailani D., Gruber A., Hanson S. R. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood: 2009; 113 4 936 944
48. Mannucci P. M., Duga S., Peyvandi F. Recessively inherited coagulation disorders. Blood: 2004; 104 5 1243 1252
49. Zadra G., Asselta R., Malcovati M., et al. Molecular genetic analysis of severe coagulation factor XI deficiency in six Italian patients. Haematologica: 2004; 89 11 1332 1340
50. Cheng Q., Kantz J., Poffenberger G., Powers A. C., Gailani D. Factor XI protein in human pancreas and kidney. Thromb Haemost: 2008; 100 1 158 160
51. Tarumi T., Kravtsov D. V., Zhao M., Williams S. M., Gailani D. Cloning and characterization of the human factor XI gene promoter: transcription factor hepatocyte nuclear factor 4alpha (HNF-4alpha) is required for hepatocyte-specific expression of factor XI. J Biol Chem: 2002; 277 21 18510 18516
52. Asselta R., Rimoldi V., Guella I., et al. Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA. Blood: 2010; 115 10 2065 2072
53. Lejeune F., Maquat L. E. Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. Curr Opin Cell Biol: 2005; 17 3 309 315
54. Thompson R. E., Mandle R. Jr, Kaplan A. P. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest: 1977; 60 6 1376 1380
55. Fujikawa K., Chung D. W., Hendrickson L. E., Davie E. W. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry: 1986; 25 9 2417 2424
56. McMullen B. A., Fujikawa K., Davie E. W. Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains. Biochemistry: 1991; 30 8 2056 2060
57. Papagrigoriou E., McEwan P. A., Walsh P. N., Emsley J. Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol: 2006; 13 6 557 558
58. Sinha D., Marcinkiewicz M., Gailani D., Walsh P. N. Molecular cloning and biochemical characterization of rabbit factor XI. Biochem J: 2002; 367 Pt 1 49 56
59. Wu W., Sinha D., Shikov S., et al. Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa. J Biol Chem: 2008; 283 27 18655 18664
60. Gailani D., Broze G. J. Jr. Factor XI activation in a revised model of blood coagulation. Science: 1991; 253 5022 909 912
61. Di Scipio R. G., Kurachi K., Davie E. W. Activation of human factor IX (Christmas factor). J Clin Invest: 1978; 61 6 1528 1538
62. von dem Borne P. AK, Meijers J. CM, Bouma B. N. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood: 1995; 86 8 3035 3042
63. Matafonov A., Sarilla S., Sun M. F., et al. Activation of factor XI by products of prothrombin activation. Blood: 2011; 118 2 437 445
64. Kannemeier C., Shibamiya A., Nakazawa F., et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A: 2007; 104 15 6388 6393
65. Smith S. A., Mutch N. J., Baskar D., Rohloff P., Docampo R., Morrissey J. H. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A: 2006; 103 4 903 908
66. Maas C., Meijers J. C., Marquart J. A., et al. Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. Proc Natl Acad Sci U S A: 2010; 107 20 9083 9087
67. Choi S. H., Smith S. A., Morrissey J. H. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood: 2011; 118 26 6963 6970
68. Whelihan M. F., Orfeo T., Gissel M. T., Mann K. G. Coagulation procofactor activation by factor XIa. J Thromb Haemost: 2010; 8 7 1532 1539
69. Saunders R. E., O'Connell N. M., Lee C. A., Perry D. J., Perkins S. J. Factor XI deficiency database: an interactive web database of mutations, phenotypes, and structural analysis tools. Hum Mutat: 2005; 26 3 192 198
70. Saunders R. E., Shiltagh N., Gomez K., et al. Structural analysis of eight novel and 112 previously reported missense mutations in the interactive FXI mutation database reveals new insight on FXI deficiency. Thromb Haemost: 2009; 102 2 287 301
71. O'Connell N. M., Saunders R. E., Lee C. A., Perry D. J., Perkins S. J. Structural interpretation of 42 mutations causing factor XI deficiency using homology modeling. J Thromb Haemost: 2005; 3 1 127 138
72. Sun M. F., Ho D., Martincic D., Ware R. E., Walsh P. N., Gailani D. Defective binding of factor XI-N248 to activated human platelets. Blood: 2007; 110 13 4164
73. Guella I., Soldà G., Spena S., et al. Molecular characterization of two novel mutations causing factor XI deficiency: A splicing defect and a missense mutation responsible for a CRM+ defect. Thromb Haemost: 2008; 99 3 523 530
74. Zivelin A., Ogawa T., Bulvik S., et al. Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activation. J Thromb Haemost: 2004; 2 10 1782 1789
75. Germanos-Haddad M., de Moerloose P., Boehlen F., Peyvandi F., Neerman-Arbez M. Homozygosity for a Thr575Met missense mutation in the catalytic domain associated with factor XI deficiency. Haematologica: 2005; 90 3 418 419
76. Sun M. F., Ho D., Martincic D., Ware R. E., Walsh P. N., Gailani D. Defective binding of factor XI-N248 to activated human platelets. Blood: 2007; 110 13 4164
77. Gailani D., Schmidt A., Sun M. F., Bolton-Maggs P. H., Bajaj S. P. A cross-reactive material positive variant of coagulation factor XI (FXIP520L) with a catalytic defect. J Thromb Haemost: 2007; 5 4 781 787
78. Bozzao C., Rimoldi V., Asselta R., et al. A novel factor XI missense mutation (Val371Ile) in the activation loop is responsible for a case of mild type II factor XI deficiency. FEBS J: 2007; 274 23 6128 6138
79. Mitchell M., Cutler J., Thompson S., et al. Heterozygous factor XI deficiency associated with three novel mutations. Br J Haematol: 1999; 107 4 763 765
80. Mitchell M. J., Dai L., Clarke J. B., Bolton-Maggs P. H., Savidge G. F., Alhaq A. Characterisation of five factor XI mutations. Thromb Haemost: 2007; 97 6 884 889
81. Mitchell M., Dai L., Savidge G., Alhaq A. An Alu-mediated 31.5-kb deletion as the cause of factor XI deficiency in 2 unrelated patients. Blood: 2004; 104 8 2394 2396
82. Asakai R., Chung D. W., Ratnoff O. D., Davie E. W. Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci U S A: 1989; 86 20 7667 7671
83. Peretz H., Zivelin A., Usher S., Seligsohn U. A 14-bp deletion (codon 554 del AAGgtaacagagtg) at exon 14/intron N junction of the coagulation factor XI gene disrupts splicing and causes severe factor XI deficiency. Hum Mutat: 1996; 8 1 77 78
84. Asakai R., Chung D. W., Davie E. W., Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med: 1991; 325 3 153 158
85. Peretz H., Salomon O., Mor-Cohen R., et al. Type I mutation in the F11 gene is a third ancestral mutation which causes factor XI deficiency in Ashkenazi Jews. J Thromb Haemost: 2013; 11 4 724 730
86. Girolami A., Scarparo P., Bonamigo E., et al. A cluster of factor XI-deficient patients due to a new mutation (Ile 436 Lys) in northeastern Italy. Eur J Haematol: 2012; 88 3 229 236
87. Kim J., Song J., Lyu C. J., et al. Population-specific spectrum of the F11 mutations in Koreans: evidence for a founder effect. Clin Genet: 2012; 82 2 180 186
88. Meijers J. C., Davie E. W., Chung D. W. Expression of human blood coagulation factor XI: characterization of the defect in factor XI type III deficiency. Blood: 1992; 79 6 1435 1440
89. Soldà G., Asselta R., Ghiotto R., Tenchini M. L., Castaman G., Duga S. A type II mutation (Glu117stop), induction of allele-specific mRNA degradation and factor XI deficiency. Haematologica: 2005; 90 1716 1718
90. Zucker M., Rosenberg N., Peretz H., et al. Point mutations regarded as missense mutations cause splicing defects in the factor XI gene. J Thromb Haemost: 2011; 9 10 1977 1984
91. Mitchell M., Harrington P., Cutler J., Rangarajan S., Savidge G., Alhaq A. Eighteen unrelated patients with factor XI deficiency, four novel mutations and a 100% detection rate by denaturing high-performance liquid chromatography. Br J Haematol: 2003; 121 3 500 502
92. Schouten J. P., McElgunn C. J., Waaijer R., Zwijnenburg D., Diepvens F., Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res: 2002; 30 12 e57
93. Weaver J. M., Edwards P. A. Targeted next-generation sequencing for routine clinical screening of mutations. Genome Med: 2011; 3 9 58
94. Rugeri L., Quélin F., Chatard B., De Mazancourt P., Negrier C., Dargaud Y. Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. Haemophilia: 2010; 16 5 771 777
95. Riddell A., Abdul-Kadir R., Pollard D., Tuddenham E., Gomez K. Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thromb Haemost: 2011; 106 3 521 527
96. Guéguen P., Galinat H., Blouch M. T., et al. Biological determinants of bleeding in patients with heterozygous factor XI deficiency. Br J Haematol: 2012; 156 2 245 251
97. Livnat T., Tamarin I., Mor Y., et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost: 2009; 102 3 487 492
98. Gomez K., Bolton-Maggs P. Factor XI deficiency. Haemophilia: 2008; 14 6 1183 1189
99. Duga S., Asselta R. Mutations in disguise. J Thromb Haemost: 2011; 9 10 1973 1976
100. Bell J., Bodmer D., Sistermans E., Ramsden S. C. Practice guidelines for the interpretation and reporting of unclassified variants (UVs) in clinical molecular genetics. Available at: http://cmgsweb.shared.hosting.zen.co.uk/BPGs/ pdfs%20current%20bpgs/UV%20GUIDELINES%20ratified.pdf. 2007. Accessed XX.
101. Fabian I. D., Sachs D., Moisseiev J., et al. Cataract extraction without prophylactic treatment in patients with severe factor XI deficiency. Am J Ophthalmol: 2009; 148 6 920 924, e1
102. Mannucci P. M., Bauer K. A., Santagostino E., et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood: 1994; 84 4 1314 1319
103. O'Connell N. M., Riddell A. F., Pascoe G., Perry D. J., Lee C. A. Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency. Haemophilia: 2008; 14 4 775 781
104. Schulman S., Németh G. An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. Haemophilia: 2006; 12 3 223 227
105. Livnat T., Zivelin A., Martinowitz U., Salomon O., Seligsohn U. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. J Thromb Haemost: 2006; 4 1 192 200
106. Mannucci P. M., Levi M. Prevention and treatment of major blood loss. N Engl J Med: 2007; 356 22 2301 2311
107. Zhang H., Löwenberg E. C., Crosby J. R., et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood: 2010; 116 22 4684 4692
108. Lin J., Deng H., Jin L., et al. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. J Med Chem: 2006; 49 26 7781 7791